Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Among TNBC ... Downstream target analysis revealed that the enzalutamide and KRLS-017 combination dramatically reduced c ...

Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. 1 Since that time, there has been tremendous effort invested in understanding the clinical features ...

MYC CNVs had an unfavorable prognostic role for both HR+/HER2− ≥4L (HR 2.41, p = 0.004) and TNBC in all lines (HR 2.14, p = 0.014). Conclusions: Our study suggests a dynamic molecular evolution of HR+ ...

These findings support the expectation that Trodelvy combined with Keytruda will become the new SOC in PD-L1-positive TNBC, shifting the frontline treatment paradigm from chemoimmunotherapy to ADC ...

Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...

Sacituzumab govitecan combined with pembrolizumab improved progression-free survival in PD-L1–positive metastatic triple-negative breast cancer compared with chemotherapy. Vepdegestrant, a ...

Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously ...

BioNTech will receive $1.5 billion upfront, $2 billion through 2028, and up to $7.6 billion in potential milestone payments. BNT327 is in global Phase 3 trials for ES-SCLC and NSCLC, with a TNBC ...

In advanced or metastatic triple-negative breast cancer with PD-L1 positivity, first-line treatment with sacituzumab govitecan plus pembrolizumab led to longer median progression-free survival (11 ...